When Japan's Sysmex disclosed two weeks ago that it had acquired molecular diagnostics services firm Inostics and flow cytometry specialist Partec, it noted that the purchases were designed to aid its foray into personalized medicine and companion diagnostics.
NEW YORK (GenomeWeb News) — Sysmex Inostics said today that it has inked a collaboration agreement with Bayer Healthcare to develop blood-based companion diagnostics for targeted anti-cancer therapies being developed by Bayer.
Japanese in vitro diagnostics firm Sysmex said this week that it has acquired a pair of German companies — molecular diagnostics services firm Inostics and flow cytometry specialist Partec — in a bid to bolster its personalized medicine and companion diagnostics development business.
A group of researchers from Massachusetts General Hospital has developed a method using either BEAMing RT-PCR or digital droplet-based PCR to detect mutations associated with glioblastoma brain tumors in RNA extracted from extracellular vesicles released from these tumors into pa
NEW YORK (GenomeWeb News) – Molecular diagnostics firm Inostics announced today that its clinical laboratory in Baltimore, Md., has received CLIA licensure, allowing it to offer its non-invasive OncoBeam tumor mutation test.
Two studies published earlier this month in Nature have demonstrated how Inostics' BEAMing digital PCR/flow cytometry technology can be used to detect drug resistance mediated by KRAS mutations in colorectal cancer patients months before treatment failure is observed.
Startups QuantaLife and Inostics join more established outfits RainDance Technologies and Life Technologies in exploring the digital PCR market, but all players will need to negotiate what is sure to be a complex intellectual property landscape.